Article
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Oncotarget - 6 Dec 2016
Riva Beatrice, De Dominici Marco, Gnemmi Ilaria, Mariani Samanta A, Minassi Alberto, Minieri Valentina, Salomoni Paolo, Canonico Pier Luigi, Genazzani Armando A, Calabretta Bruno, Condorelli Fabrizio
Abstract excerpt
CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue. The anti-inflammatory COX2 inhibitor celecoxib has been utilized as anti-tumour drug due to its anti-proliferative activity. However, its effects in hematological malignancies, in particular CML, have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.